after Isolated Rapid Deployment Aortic Valve Replacement

Slides:



Advertisements
Similar presentations
MINIMALLY INVASIVE AORTIC VALVE REPLACEMENT ANTONIO MICELI DEPARTMENT OF CARDIOTHORACIC SURGERY FONDAZIONE TOSCANA G. MONASTERIO MASSA, ITALY.
Advertisements

(1) Arch Debranching vs. Elephant Trunk for Hybrid Repair of the Proximal Thoracic Aorta Arch Debranching versus Elephant Trunk Procedures for Hybrid Repair.
Background (1) ・ In 1998, we developed a modified elephant trunk (ET) technique using a single four-branched arch graft with a sewing “collar” and “long.
STS 2015 John V. Conte, MD Professor of Surgery Johns Hopkins University School of Medicine On Behalf of the CoreValve US Investigators Transcatheter Aortic.
Conventional and frozen elephant trunk surgery for extensive aneurysmal disease of the thoracic aorta: a retrospective comparative study Marco Di Eusanio.
Results of “Type II” Hybrid Arch Repair with Zone 0 Stent Graft Deployment Jehangir Appoo, William Kent, Eric Herget, Jason Wong, Alberto Pochettino and.
Three-year clinical and echocardiographic follow-up of aortic stenosis patients implanted with a self-expending bioprosthesis Sabine Bleiziffer German.
ACC 2015 Michael J Reardon, MD, FACC On Behalf of the CoreValve US Investigators A Randomized Comparison of Self-expanding Transcatheter and Surgical Aortic.
Use of Psoas Muscle Size as a Frailty Assessment Tool for Open and Transcatheter Aortic Valve Replacement Raghavendra Paknikar BS Jeffrey Friedman BS David.
INTERNATIONAL. CAUTION: For distribution only in markets where CoreValve® is approved. Not for distribution in U.S., Canada or Japan. Medtronic, Inc
How to Avoid Prosthesis-Patient Mismatch
University Heart Center Hamburg
M Ruel, V Chan, M Boodhwani, B McDonald, X Ni, G Gill, K Lam, F Rubens, P Hendry, R Masters, T Mesana Ottawa, Canada How Detrimental is Re-Exploration.
Aortic Root Surgery Trends in the US: Report From the STS Database Sotiris C. Stamou, MD, Ph.D, Mathew L. Williams, MD, Yue Zhao, Ph.D, Nicholas T. Kouchoukos,
The Use of Thoracic Endovascular Stent Grafting in Acute Aortic Tragedies as Compared to Open Surgical Repair Tyler J. Wallen, BA, Wilson Y. Szeto, MD,
Sakakibara Heart Institute Minoru Tabata, MD, MPH, Akihito Matsushita, MD, Toshihiro Fukui, MD, Shigefumi Matsuyama, MD, Tomoki Shimokawa, MD, Shuichiro.
The Synergy between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery: The SYNTAX Study One Year Results of the PCI and CABG Registries.
after Isolated Rapid Deployment Aortic Valve Replacement
One-stage repair for Stanford Type B Aortic Dissection concomitant with cardiac diseases Open stented elephant trunk technique combined with cardiac operation.
TCT 2015 | San Francisco | October 15, 2015 Transcatheter Aortic Valve Replacement for Failed Surgical Bioprostheses Danny Dvir, MD John G. Webb, MD and.
Does Operative Technique of Performing Distal Anastomosis in Acute type A Dissection Affect Early And Late Clinical Outcomes? Sotiris C. Stamou, MD, Ph.D,
UC c EN. Through Medtronic sponsored research, the Transcatheter Aortic Valves clinical portfolio is studying over 11,000 subjects at over 125.
TOTAL AORTIC ARCH REPLACEMENT WITH THORAFLEX HYBRID FROZEN ELEPHANT TRUNK PROSTHESIS: RESULTS OF FIRST 100 PATIENTS Malakh Shrestha, Heike Krueger, Tim.
The Reoperative Aortic Root: Degenerative Failure vs. Infectious Destruction – Outcomes of The “True Redo-Root” Reconstruction Rita K. Milewski, Arminder.
M.H. Nezafati Associate Professor of Cardiac Surgery
Longest Follow-up After Implantation of a Self-Expanding Repositionable Transcatheter Aortic Valve: Final Follow-up of the Evolut R CE Study Stephen Brecker,
G. Michael Deeb, MD On Behalf of the CoreValve US Investigators
Outcomes in the CoreValve US High-Risk Pivotal Trial in Patients with a Society of Thoracic Surgeons Predicted Risk of Mortality Less than or Equal to.
Patients at intermediate surgical risk undergoing isolated interventional or surgical aortic valve replacement for severe symptomatic aortic valve stenosis.
The German Off-Pump Coronary Artery Bypass Grafting in
Current Surgical Standards for Mitral Leaflet and Chordal Repair: Patient Selection,Techniques and Clinical Outcomes CRT February 2011 Niv Ad, MD Chief,
Minimally Invasive Mitral Valve Repair
Early Surgery versus Conventional Treatment for Infective Endocarditis
Patients Characteristics
TRANSFORM (Multicenter Experience With Rapid Deployment Edwards INTUITY Valve System for Aortic Valve Replacement) US clinical trial: Performance of a.
Initial center experience with the St
Updates From NOTION: The First All-Comer TAVR Trial
TAVR-Endocarditis Tarek Chami, MD
Lako S, Daka A, Nurka T, Dedej T, Memishaj S
Transcatheter or Surgical Aortic Valve Replacement in Intermediate Risk Patients with Aortic Stenosis Description: The goal of the trial was to assess.
MedStar Washington Hospital Center Cardiac Catheterization Conference
Trans-Apical Aortic Valve Implant:
Is There a Need to Address AF in patients Undergoing Valve Surgery?
First Report of Three-Year Outcomes With the Repositionable and Fully Retrievable Lotus™ Aortic Valve Replacement System: Results From the REPRISE I.
Early Outcomes with the Evolut R Repositionable Self-Expanding Transcatheter Aortic Valve in the United States Mathew Williams, MD, For the Evolut R US.
University of Pennsylvania
Benefits of minimally invasive aortic valve replacement (MIS-AVR)
Aortic Root Surgery Trends in the US: Report From the STS Database
Choosing the valve type for AVR in old patients.
Niv Ad, MD Chief, Cardiac Surgery Professor of Surgery, VCU
CoreValve Continued Access Study Shows Continued Improvement in 1-Year Outcomes With Self-Expanding Transcatheter Aortic Valve Replacement Steven J. Yakubov,
Axel Linke University of Leipzig Heart Center, Leipzig, Germany
One Year Outcomes in Real World Patients Treated with Transcatheter Aortic Valve Implantation The ADVANCE Study Axel Linke University of Leipzig Heart.
University Heart Center Hamburg
Balloon-Expandable Transcatheter Valve System : OUS Data
Laparoscopic vs Open Colonic Surgery: Long Term Survival
Rapid deployment or sutureless versus conventional bioprosthetic aortic valve replacement: A meta-analysis  Suk Ho Sohn, MD, Myoung-jin Jang, PhD, Ho.
Late Follow-Up from the PARTNER Aortic Valve-in-Valve Registry
A Randomized Multicenter Trial of Minimally Invasive Rapid Deployment Versus Conventional Full Sternotomy Aortic Valve Replacement  Michael A. Borger,
Sorin Bicarbon: 17 years of clinical use
The Synergy between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery: The SYNTAX Study One Year Results of the PCI and CABG Registries.
Sergey Leontyev, MD, Thomas Walther, MD, PhD, Michael A
The Synergy between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery: The SYNTAX Study One Year Results of the PCI and CABG Registries.
Rapid-deployment valves: Finally the fog is lifting-benefits beyond crossclamp and bypass times  Günther Laufer, MD, PhD, Dominik Wiedemann, MD, Walter.
Postoperative Outcome of Isolated Tricuspid Valve Operation Using Arrested-Heart or Beating-Heart Technique  Bettina Pfannmüller, MD, Piroze Davierwala,
TRANSFORM (Multicenter Experience With Rapid Deployment Edwards INTUITY Valve System for Aortic Valve Replacement) US clinical trial: Performance of a.
Minimal access aortic valve replacement: effects on morbidity and resource utilization  Nicolas Doll, MD, Michael A Borger, MD, PhD, Joerg Hain, Jan Bucerius,
One-year outcomes of the Surgical Treatment of Aortic Stenosis With a Next Generation Surgical Aortic Valve (TRITON) trial: A prospective multicenter.
T Salah, MD., M Saber, MBBCh., T ElTaweil, MD. and N Rasmy,MD.
Presentation transcript:

after Isolated Rapid Deployment Aortic Valve Replacement Comparison of Procedural Outcomes and Early Safety by Surgical Approach after Isolated Rapid Deployment Aortic Valve Replacement Thorsten C.W. Wahlers, M.D., Ph.D.,1 Axel Haverich, M.D.,2 Michael A. Borger, M.D., Ph.D.3 Malakh Shrestha, M.B.B.S, Ph.D.,2 Alfred A. Kocher, M.D.,4 Thomas Walther, M.D., Ph.D.,5 Matthias Roth, M.D.,5 Martin Misfeld, M.D.,3 Friedrich W. Mohr, M.D., Ph.D.,3 Joerg Kempfert, M.D.,5 Pascal M. Dohmen, M.D., Ph.D.,6 Christoph Schmitz, M.D.,7 Parwis Rahmanian, M.D.,1 Dominik Wiedemann, M.D.,4 Francis G Duhay, M.D.,8 Günther Laufer, M.D.4   1Medical University of Cologne, Cologne, Germany, 2Medical University of Hannover, Hannover, Germany, 3Heart Center Leipzig, Leipzig, Germany, 4Medical University of Vienna, Vienna, Austria, 5Kerckhoff Klinik, Bad Nauheim, Germany, 6University of Leipzig, Leipzig, Germany, 7University of Munich, Munich, Germany, 8Edwards Lifesciences LLC, Irvine, CA, USA

Background Aortic valve replacement through a minimal access approach is associated with favorable clinical outcomes1-3 However, several meta-analyses have reported significantly longer cross-clamp times compared to a full sternotomy1, 4 References 1. Brown et al., J Thorac Cardiovasc Surg. 2009;137:670-679 e5. 2. Machler et al. Ann Thorac Surg. 1999;67:1001-5. 3. Albacker et al. J Thorac Cardiovasc Surg. 2014;147:355-361.e5. 4. Phan K, et al., Ann Thorac Surg. 2014;98:1499-511.

Purpose In patients enrolled in the TRITON trial, we examined procedural and early (<30 days) safety outcomes after isolated rapid deployment aortic valve replacement through Full Sternotomy Upper Hemisternotomy Right Anterior Thoracotomy

Methods Prospective, multicenter single arm study (Hannover, Cologne, Leipzig, Vienna, Bad Nauheim, Munich) 287 patients with symptomatic, severe aortic stenosis underwent RDAVR using the EDWARDS INTUITY Valve System Inclusion criteria: age ≥ 18 yrs; AS ± AR; elective AVR ± concomitant procedure(s); informed consent; agree to f/u for 5 yrs Exclusion criteria: Pure AR; concomitant valve disease, or aneurysm of aortic root or ascending aorta requiring surgery; life-expectancy < 12 mos Patients were operated between January 2010 & October 2012 For the purposes of this study, patients were evaluated for: Perioperatively, for procedural times and technical success rates At discharge, for hospital length of stay At 30 days, for early adverse events

EDWARDS INTUITY Overview A rapid deployment technique that incorporates a subannular, balloon-expandable stent frame that mechanically widens the LVOT to ensure a larger EOA compared to conventional surgical valves

Triton Study Overview Technical Success 96.1% 98.6% 97.3% Enrollment Gen I Valve n=149 Gen II Valve n=138 Combined n=287 Technical Success (Deployment of the study valve within two attempts) 96.1% (149/155) 98.6% (138/140) 97.3% (287/295)

Surgical Approach Overview Number of Cases by Surgical Approach Enrollment n=295 158 (55%) Isolated AVR 71 (45%) Full Sternotomy 87 (55%) Minimal Access Incision 77 (89%) Upper Hemisternotomy 10 (11%) Right Anterior Thoracotomy

Results: Baseline Characteristics Enrollment n=295 Technical Success FS - 97.2% (71/73) UHS - 97.4% (77/79) RAT -100% (10/10) Isolated RDAVR n=158 Delivery and deployment of the study valve within two attempts Parameter Full Sternotomy (n=71) Upper Hemisternotomy (n=77) Right Anterior Thoracatomy (n=10) Age,yrs 75.7 ± 6.8 75.6 ± 6.6 75.3 ± 13.5 FEMALE 49.3 % (35/71) 50.6 % (39/77) 60.0 % (6/10) Logistic EuroSCORE, % 8.0 ± 6.4 7.9 ± 4.9 12.0 ± 14.8 Body Mass Index, kg/m2 28.7 ± 4.2 27.8 ± 4.4 25.7 ± 3.4 Body Surface Area, m2 2.0 ± 0.2 1.9 ± 0.2 LVEF, % 63 ± 11 58 ± 13 59 ± 8 TRITON Database as of 17-June-2014

Results: Distribution of Valve Sizes mean 23.3 mm mean 23.6 mm TRITON Database as of 17-June-2014

Results: Early Safety Outcomes Parameter Full Sternotomy Upper Hemisternotomy Right Anterior Thoracatomy All Cause Mortality 1.4% (1/71) 1.3% (1/77) 0.0% (0/10) Study Valve Related Mortality Reoperation for Bleeding 7.0% (5/71) 7.8% (6/77) Renal Failure/Dysfunction 2.8% (2/71) 9.1% (7/77) Thromboembolic Event Deep Sternal Wound Infection Respiratory Dysfunction 3.9% (3/77) Major Bleeding Events 11.3% (8/71) 6.5% (5/77) Study Valve Related Explant PVL Requiring Surgical Intervention 0.0% (0/71) Pacemaker Implants,Total 5.6% (4/71) 5.2% (4/77) Valve Related Pacemaker Implants 4.2% (3/71) 2.6% (2/77) TRITON Database as of 17-June-2014

Results: Procedural Times Parameter FS (n=71) UHS (n=77) RAT (n=10) p-value FS vs. UHS p-value FS vs. RAT Cardiopulmonary by-pass time (min) 71.6±41.8 69.6±19.1 122.2±22.1 0.2639 <.0001 Cross-clamp time (min) 43.5±32.5 43.1±13.1 88.3±18.6 0.1306 FS, full sternotomy; UHS, upper hemisternotomy; RAT, right anterior thoracatomy TRITON Database as of 17-June-2014

Results: Procedural Times II Comparison of Cross-clamp times to the Literature EDWARDS INTUITY Upper Hemisternotomy REFERENCE CROSS-CLAMP TIME (MIN) TRITON 43 Borger1 41 Schlomicher2 26 Overall 26 – 43 min Surgical Valves Upper Hemisternotomy REFERENCE CROSS-CLAMP TIME (MIN) Tabata1 72 Bakir2 62 Brinkmann3 75 Overall 62 – 75 min Borger et al. Ann Thorac Surg. 2015;99:17-25. Schlomicher et al. J Thorac Cardiovasc Surg. 2015 Feb;149(2):434-40. Tabata et al. Asian cardiovascular & thoracic annals. 2007;15:225-8. Bakir et al. Ann Thorac Surg. 2006 May;81(5):1599-604. Brinkman et al. Ann Thorac Surg. 2010;90:131-5. TRITON Database as of 17-June-2014

Results: Discharge Outcomes Parameter FS (n=69) mean ± sd (min, max) median UHS (n=76) RAT (n=10) P-value FS vs. UHS FS vs. RAT Hospital LOS (days) 11.7±6.3 (6.0, 50.0)10.0 13.1±10.6 (5.0, 89.0)10.0 9.5±6.7 (5.0, 28.0)7.0 0.8189 0.0116 ICU LOS (hours) 61.7±115.4 (0.0, 664.0)24.0 59.1±102.9 (0.0, 625.0)23.0 33.6±12.4 (24.0, 48.0)24.0 0.0936 0.5658 Intermediate Care LOS (hours) 22.3±45.1 (0.0, 192.0)0.0 43.7±92.8 (0.0, 504.0)0.0 19.2±42.0 (0.0, 120.0)0.0 0.1258 0.5940 In-hospital mortality 2.8% (2/71) 1.3% (1/77) 0.0% (0/10) 0.6076* 0.9999* P-values based on Wilcoxon * indicates use of Fisher's Exact test to calculate the P-values LOS, length of stay; FS, full sternotomy; UHS, upper hemisternotomy; RAT, right anterior thoracatomy TRITON Database as of 17-June-2014

Reoperation 19 mm Valve degenerated 21 mm Intuity Valve, 44 Min Reoperation 19 mm Valve degenerated 21 mm Intuity Valve, 44 Min. Clamptime

Conclusions Isolated RDAVR through an upper hemisternotomy can lead to shorter cross-clamp times than than have been historically reported in the surgical literature This benefit may facilitate minimally invasive AVR by lessening the concern over prolonged cross-clamp times Regardless of surgical approach, isolated RDAVR with EDWARDS INTUITY may lead to… Low in-hospital mortality rate Low early (<30 days) mortality rate Low new permanent pacemaker implant rate

Limitations TRITON represents initial experience using EDWARDS INTUITY Valve System; hence, incorporates learning curve Lack of active comparator group

Thank you for the attention. thorsten.wahlers@uk-koeln.de